Brenipatide

Pharmaceutical compound From Wikipedia, the free encyclopedia

Brenipatide (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name LY-3537031) is a dual agonist of glucagon-like peptide-1 (GLP-1) receptors and gastric inhibitory polypeptide (GIP) receptors.

Other namesLY-3537031; LY3537031
Routes of
administrationSubcutaneous injection[1][2]
Drug classGLP-1 receptor agonist; GIP receptor agonist
CAS Number
Quick facts Clinical data, Other names ...
Brenipatide
Clinical data
Other namesLY-3537031; LY3537031
Routes of
administration		Subcutaneous injection[1][2]
Drug classGLP-1 receptor agonist; GIP receptor agonist
Identifiers
  • D-Tyrosyl-2-methylalanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-2-methyl-L-leucyl-L-leucyl-L-α-aspartyl-L-lysyl-N6-[N-(19-carboxy-1-oxononadecyl) -L-γ-glutamyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-2-[2-(2-aminoethoxy)ethoxy]acetyl] -L-lysyl-L-alanyl-L-glutaminyl-2-methylalanyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-α-glutamyl-α-methyl-L-tyrosyl-L-leucyl-L-isoleucyl-L-alanylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-serinamide
CAS Number
PubChem SID
UNII
Chemical and physical data
FormulaC228H354N46O72
Molar mass4891.590 g·mol−1
Close

Brenipatide is under development by Eli Lilly and Company for the treatment of alcoholism, bipolar disorder, asthma, smoking withdrawal, cardiovascular disorders, liver disorders, metabolic disorders, and obesity.[1][3][4][2]

It is taken by subcutaneous injection once per month.[1][4][2] The drug has a longer elimination half-life than tirzepatide or retatrutide.[2]

As of December 2025, it was in phase 3 clinical trials for alcoholism and bipolar disorder, phase 2 trials for asthma and smoking withdrawal, and phase 1 trials for cardiovascular disorders, liver disorders, metabolic disorders, and obesity.[1][4]

See also

References

Related Articles

Wikiwand AI